Key result
Serum from patients in the acute phase of septic shock induced a 33% decrease in the extent of myocardial cell shortening in vitro compared to control sera, which correlated with decreased in vivo ejection fraction.
Why the study?
Does serum from patients with septic shock contain a circulating factor that depresses myocardial cell performance?
Observational (n=59)
No
Does serum from patients with septic shock contain a circulating factor that depresses myocardial cell performance?
Absolute Event Rate: -33% vs -0.6%
p-value: p=<0.001
No takes yet. Share an insight, caveat, or question.
Supports circulating myocardial depressant factor in septic shock; leaves open clinical relevance and therapeutic targeting.
Parrillo et al. (1985) conducted an observational in Septic shock (n=59). Acute phase septic shock serum vs. Critically ill nonseptic control serum was evaluated on Percent change in extent of myocardial cell shortening (p=<0.001). Serum from patients in the acute phase of septic shock induced a 33% decrease in the extent of myocardial cell shortening in vitro compared to control sera, which correlated with decreased in vivo ejection fraction.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: